✦ LIBER ✦

Frequency of the basal-like phenotype in African breast cancer

✍ Scribed by HAWA NALWOGA; JARLE B. ARNES; HENRY WABINGA; LARS A. AKSLEN

Book ID: 109343604
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 144 KB
Volume: 115
Category: Article
ISSN: 0365-5555
DOI: 10.1111/j.1600-0463.2007.00862.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Basal-like breast cancer and the BRCA1 p

Basal-like breast cancer and the BRCA1 phenotype

✍ Turner, N C; Reis-Filho, J S 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 201 KB

Sox2: a possible driver of the basal-lik

Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer

✍ Rodriguez-Pinilla, Socorro M; Sarrio, David; Moreno-Bueno, Gema; Rodriguez-Gil, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 233 KB

Ductal carcinoma in situ with basal-like

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer

✍ Bryan, Bradley B; Schnitt, Stuart J; Collins, Laura C 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 138 KB

BRCA1 transcriptionally regulates genes

BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer

✍ Julia J. Gorski; Colin R. James; Jennifer E. Quinn; Gail E. Stewart; Kieran Cros 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 702 KB

Prognostic Value of Basal Phenotype in H

Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer

✍ Sanjay P. Bagaria; Partha S. Ray; Jinhua Wang; Luisa Kropcho; Alice Chung; Myung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 481 KB

PI3K pathway activation in breast cancer

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

✍ Elena López-Knowles; Sandra A. O'Toole; Catriona M. McNeil; Ewan K.A. Millar; Mi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 552 KB

## Abstract Breast cancer is a common malignancy with current biological therapies tailored to steroid hormone (ER, PR) and HER2 receptor status. Understanding the biological basis of resistance to current targeted therapies and the identification of new potential therapeutic targets is an ongoing